Cancers are often caused by alterations in specific genes that result in abnormal proteins that drive cell growth and proliferation.
Some people develop cancers that are solely reliant on a cellular pathway, turned on inappropriately by a single DNA change. When a genomic test identifies a patient with a so-called “oncogenic driver,” there should be a targeted therapy to address the problem. At Loxo Oncology, our goal is to develop a pipeline of highly selective and well-behaved drugs that inhibit oncogenic drivers in cancer.
As scientists learn more about the genomic drivers of cancer, we can find more opportunities to treat cancer, in particular by matching patients to the best therapies for their particular cancer. The increasing use of genomic testing is providing a more precise look at the underlying genomics of each cancer patient and helping to guide medical decisions and treatment.